PET in primary pulmonary or pleural cancer;La TEP dans les cancers bronchopulmonaires ou pleuraux primitifs

Presse Medicale

Volumn 35, Issue 9 II, 2006, Pages 1387-1400

  Talbot, Jean Noël ^a,b   Kerrou, Khaldoun ^a   Grahek, Dany ^a   Balogova, Sona ^a   Gounant, Valérie ^a,b   Lavole, Armelle ^a,b   Gutman, Fabrice ^a   Aflalo Hazan, Vanessa ^a   Raileanu, Irena ^a   Montravers, Françoise ^a   Mayaud, Charles ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVALUATION; FOLLOW UP; HUMAN; LUNG CARCINOMA; LUNG NODULE; LUNG NON SMALL CELL CANCER; REVIEW;

EID: 33748661694     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74822-9     Document Type: Review

References (68)

1. Hain SF, Curran KM, Beggs AD, Fogelman I, O'Doherty MJ, Maisey MN. FDG-PET as a "metabolic biopsy" tool in thoracic lesions with indeterminate biopsy. Eur J Nucl Med. 2001; 28 (9): 1336-40.
2. Pitman AG, Hicks RJ, Binns DS, Ware RE, Kalff V, McKenzie AF et al. Performance of sodium iodide based [18F]-fluorodeoxyglucose positron emission tomography in the characterisation of indeterminate pulmonary nodules or masses. Brit J Radiol. 2002; 75 (890): 114-21.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001; 42(S5): 2S-8S.
4. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest. 1995; 108: 441-6.
5. Kazerooni EA, Lim FT, Mikhail A, Martinez FJ. Risk of pneumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology. 1996; 198: 371-5.
6. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary modules and mass lesions. A meta-analysis. JAMA. 2001; 285: 914-24.
7. Perrotin C, Lemeunier P, Grahek D, Molina T, Petino A, Alifano M et al. Résultats de la TEP [18F]-FDG dans la stadification préopé ratoire des tumeurs pulmonaires. Rev Mal Respir. 2005; 22 (4): 579-85.
8. Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 2002; 36 (3): 297-301.
9. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002; 359: 1388-93.
10. Verboom P, Uyl-de Groot CA, Erasmus MC. The role of FDG-PET in the staging of non-small cell lung cancer from a health technology perspeclive. Eur J Nucl Med. 2005; 32 (S1): S103, abstract no 391.
11. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ et al. Prognosis importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999; 17: 3201-6.
12. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K, Lammertsma AA et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005; 41: 1533-41.
13. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol. 1998; 170: 1369-73.
14. Kim BT, Kim Y, Lee KS, Yoon SB, Cheon EM, Kwon OJ et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. Am J Roentgenol. 1998; 170: 935-9.
15. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998; 39 (6): 1016-20.
16. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med. 2002; 29 (9): 1166-73.
17. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (> 3 cm) lymph node lesions. Chest. 2000; 117 (3): 773-8.
18. Grahek D, Montravers F, Kerrou K, Talbot JN. Contribution of the FDG scintigraphy on a dual head coincidence gammacamera (CDET) to the characterisation of pulmonary lesions and staging of lung cancer. Eur J Nucl Med. 1999; 26(9), 1036 (résumé OS304).
19. Herder GJ, Golding RP, Hoekstra OS, Comans EF, Teule GJ, Postmus PE et al. The performance of 18F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med. 2004; 31: 1231-6.
20. Webb WR, Gatsonis C, Zerhouni EA, Heelan RT, Glazer GM, Francis IR et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiological Diagnostic Oncology Group. Radiology. 1991; 178: 705-13.
21. Pozo-Rodriguez F, Martin de Nicolas JL, Sanchez-Nistal MA, Maldonado A, Garcia de Barajas S, Calero-Garcia R et al. Accuracy of helical computed tomography and [18F] fluorodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small cell lung caner. J Clin Oncol. 2005; 23: 8348-56.
22. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H et al. Non-small cell lung cancer: dual modality PET/CT in preoperative staging. Radiology. 2003; 229: 526-33.
23. Giacomuzzi F, Rocco M, Lugatti E et al. Lymph node staging with FDG-PET-CT in non-small cell lung cancer (NSCLC): our experience in 106 patients. Eur J Nucl Med. 2005; 32: S105, abstract no401.
24. Takamochi K, Yoshida J, Murakami K, Niho S, Ishii G, Nishimura M et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer. 2005; 47: 235-42.
25. Poncelet AJ, Lonneux M, Coche E, Weynand B, Noirhomme P; Groupe d'Oncologie Thoracique des Cliniques Saint-Luc. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg. 2001; 20: 468-74.
26. Kernstine KH, Mclaughlin KA, Menda Y, Rossi NP, Kahn DJ, Bushnell DL et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable non-small cell lung cancer? Ann Thorac Surg. 2002; 73 (2): 394-401.
27. Marom EM, Erasmus JJ, Patz EF. Lung cancer and positron emission tomography with fluorodeoxyglucose. Lung Cancer. 2000; 28 (3): 187-202.
28. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Engl J Med. 2000; 343: 254-61.
29. Eschmann SM, Friedel G, Paulsen F, Budach W, Harer-Mouline C, Dohmen BM et al. FDG PET for staging of advanced non-small lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med. 2002; 29: 804-8.
30. Kamel EM, McKee TA, Calcagni ML, Schmidt S, Markl S, Castaldo S et al. Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies. Eur J Nucl Med. 2005; 32: 641-6.
31. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999; 212: 803-9.
32. Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004; 45: 2058-62.
33. Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD. FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging. 2006; 33: 29-35.
34. Aflalo-Hazan V, Gutman F, Raileanu I et al. TEP au 18F-FDG et scintigraphie du squelette dans la recherche de métastases osseuses du cancer bronchopulmonaire. Rev Pneumol Clin. 2006; 62 (3): 164-9.
35. Buck AK, Blumstein NM, Hasenkamp E et al. Detection of bone metastases from non-small cell lung cancer with FDG-PET/CT - Can it replace functional imaging of bone? Eur J Nucl Med. 2005; 32: S116, abstract no 453.
36. Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med. 2004; 31: 1614-20.
37. Goldfarb CR, Guelfguat M, Edelstein Y et al. Distribution of bone metastases in lung cancer. J Nucl Med. 1999; 40: 258 P, abstract no 1144.
38. 18F]fluoroethyl)-L-tyrosine and L-[methyl-11C] methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000; 27: 542-9.
39. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison With 18F-FDG. J Nucl Med. 2005; 46: 945-52.
40. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M et al. [18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003; 30: 1407-12.
41. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE et al. Prognosis relevance of response evaluation using [18F]-2-fluoro-2-déoxy-D-glucose positron emission tomography in patients with locally advanced non-small cell lung cancer. J Clin Oncol. 2005; 23: 8362-73.
42. Hellwig D, Groschel A, Graeter TP, Hellwig AP, Nestle U, Schafers HJ et al. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006; 33: 13-21.
43. Zhao J, Gun YH, Lu S, Zvo CT, Lin XT. Detection of recurrent non-small cell lung cancer with integrated 18F-FDG PET/CT. Eur J Nucl Med. 2005; 32 (S1): S105, abstract no403.
44. Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE et al. Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001, 19: 111-8.
45. Talbot JN, Rain JD, Meignan M, Askienazy S, Grall Y, Bok B et al. Impact de la TEP au FDG- (18F) sur la décision médicale en cancérologie: évaluation par les prescripteurs durant la première année de fonctionnement. Bull Cancer. 2002; 89: 313-21.
46. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME et al. The impact of PET on management of lung cancer: the referring physician's perspective. J Nucl Med. 2002; 43: 752-6.
47. Talbot JN, Cailleux N, Montravers F, Grahek D, Kerrou K. Impact de la TEP au 18F-FDG sur la décision thérapeutique en cancérologie: étude prospective par questionnaire de 2001 à 2004. Med Nucl. 2005; 29: 727 (résumé P080).
48. Kiffer JD, Berlangieri SU, Scott AM, Quong G, Feigen M, Schumer W et al. The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 1998; 19: 167-77.
49. Giraud P, Grahek D, Montravers F, Carette MF, Deniaud-Alexandre E, Julia F et al. CT and 18F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers, Int J Radiat Oncol Biol Phys. 2001; 49: 1249-57.
50. Deniaud-Alexandre E, Touboul E, Lerouge D, Grahek D, Foulquier JN, Petegnief Y et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 1432-41.
51. Caldwell CB, Mah K, Ung YC, Danjoux CE, Balogh JM, Ganguli SN et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small cell lung tumors on CT: the impact of 18FDG hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001; 51: 923-31.
52. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert HC. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003; 44: 1911-7.
53. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol. 2004; 27: 164-71.
54. Balogova S, Grahek D, Kerrou K, Montravers F, Younsi N, Aide N et al. L'imagerie nucléaire au [18F]-FDG dans les lésions pleurales en apparence isolées. Rev Pneumol Clin. 2003, 59: 275-88.
55. Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Radermecker MF. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax. 1997; 52: 187-9.
56. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest. 1998; 114: 713-22.
57. Buchmann I, Guhlmann CA, Elsner K, Gfrorer W, Schirrmeister H, Kotzerke J et al. [F18]-FDG PET for primary diagnosis differential diagnosis of pleural processes. Nuklearmedizin. 1999; 38: 319-22.
58. Schneider DB, Clary-Macy C, Challa S, Sasse KC, Merrick SH, Hawkins R et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000; 120: 128-33.
59. Carretta A, Landoni C, Melloni G, Ceresoli GL, Compierchio A, Fazio F et al. 18-FDG positron emision tomography in the ev aluation of malignant pleural diseases: a pilot study. Eur J Cardiothorac Surg. 2000; 17: 377-83.
60. 18f]-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002; 43: 1144-9.
61. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 1999; 40: 1241-5.
62. Ng DCE, Hain SF, O'Doherty MJ, Dussek J. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 2000; 41: 1443-4.
63. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg. 2005; 129: 1364-70.
64. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer. 2005; 49 Suppl 1: S27-32.
65. Sugarbaker DJ, Norberto JJ, Swanson SJ. Extrapleural pneumonectomy in the setting of multimodality therapy for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997; 9: 373-82.
66. Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C et al. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm. 2004; 19: 149-54.
67. Reske SV, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German interdisciplinary consensus conference, "Onko-PET III". Eur J Nucl Med. 2001; 28: 1707-23.
68. Bourguet P et le groupe SOR TEP-FDG. Standards, options et recommandations. 2002 pour l'utilisation de la tomographie par émission de positons au [18F]-FDG (TEP-FDG) en cancérologie. Bull Cancer. 2003; 90: S67-S79.